{"id":22892,"date":"2018-01-14T08:27:49","date_gmt":"2018-01-14T02:57:49","guid":{"rendered":"https:\/\/cardiophile.org\/?p=22892"},"modified":"2022-08-23T19:50:16","modified_gmt":"2022-08-23T14:20:16","slug":"ulinastatin-cardiology-mcq-answer","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/","title":{"rendered":"Ulinastatin – Cardiology MCQ – Answer"},"content":{"rendered":"

Ulinastatin – Cardiology MCQ – Answer<\/strong><\/span><\/h2>\n

Ulinastatin is a (choose the correct answer):<\/strong><\/span>
\nCorrect answer:<\/strong><\/span><\/p>\n

    \n
  1. Urinary trypsin inhibitor<\/li>\n<\/ol>\n

    Higher plasma levels of neutrophil elastase and markedly activated neutrophils have been associated with poor response to intravenous immunoglobulin (IVIG) and coronary artery lesions in Kawasaki disease. Ulinastatin<\/strong>, a urinary trypsin inhibitor<\/em><\/strong> has been used as a suppressor of neutrophils<\/em><\/strong>.
    \nA retrospective study by Kanai T et al [1] evaluated the benefits of this drug in Kawasaki disease. They could identify 369 patients who were treated with a combination of ulinastatin, intravenous immunoglobulin and aspirin. 1178 patients who were treated with IVIG and aspirin served as the control group. They found that those treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01).
    \nThe drug has been tried in other conditions like pancreatitis, multiorgan dysfunction syndrome, sepsis and post operative cognitive dysfunction. It is considered as an immunomodulator in some of this conditions. Its anti inflammatory effects are dependent on inhibition of neutrophil derived elastase, tumour necrosis factor alpha, pro-inflammatory cytokines and interleukins. It can also suppress activation of macrophages and platelets. The medications has been approved in Japan. Clinical trials are progressing across the globe. Use in Kawasaki disease at present can be considered as an off label use.
    \nBack to question<\/a>
    \nReference<\/strong><\/span><\/p>\n

      \n
    1. Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011 Dec 20;124(25):2822-8. More references…<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Ulinastatin – Cardiology MCQ – Answer: 1. Urinary trypsin inhibitor<\/p>\n","protected":false},"author":1,"featured_media":17497,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[3,5],"tags":[],"class_list":["post-22892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology-mcq","category-dm-dnb-cardiology-entrance"],"yoast_head":"\nUlinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"description\" content=\"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ulinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-14T02:57:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-23T14:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"701\" \/>\n\t<meta property=\"og:image:height\" content=\"517\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Ulinastatin – Cardiology MCQ – Answer\",\"datePublished\":\"2018-01-14T02:57:49+00:00\",\"dateModified\":\"2022-08-23T14:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/\"},\"wordCount\":271,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cardiology-mcq1.png\",\"articleSection\":[\"Cardiology MCQ\",\"DM \\\/ DNB Cardiology Entrance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/\",\"name\":\"Ulinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cardiology-mcq1.png\",\"datePublished\":\"2018-01-14T02:57:49+00:00\",\"dateModified\":\"2022-08-23T14:20:16+00:00\",\"description\":\"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cardiology-mcq1.png\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cardiology-mcq1.png\",\"width\":701,\"height\":517},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-cardiology-mcq-answer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ulinastatin – Cardiology MCQ – Answer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ulinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders","description":"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/","og_locale":"en_US","og_type":"article","og_title":"Ulinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders","og_description":"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)","og_url":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2018-01-14T02:57:49+00:00","article_modified_time":"2022-08-23T14:20:16+00:00","og_image":[{"width":701,"height":517,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png","type":"image\/png"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Ulinastatin – Cardiology MCQ – Answer","datePublished":"2018-01-14T02:57:49+00:00","dateModified":"2022-08-23T14:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/"},"wordCount":271,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png","articleSection":["Cardiology MCQ","DM \/ DNB Cardiology Entrance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/","url":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/","name":"Ulinastatin - Cardiology MCQ - Answer - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png","datePublished":"2018-01-14T02:57:49+00:00","dateModified":"2022-08-23T14:20:16+00:00","description":"Ulinastatin is a urinary trypsin inhibitor. Ulinastatin has been used as a suppressor of neutrophils. Patients with Kawasaki disease treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01)","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2014\/10\/cardiology-mcq1.png","width":701,"height":517},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-cardiology-mcq-answer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Ulinastatin – Cardiology MCQ – Answer"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=22892"}],"version-history":[{"count":3,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22892\/revisions"}],"predecessor-version":[{"id":54698,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22892\/revisions\/54698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/17497"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=22892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=22892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=22892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}